Nymox on track to file fexapotide applications in ~four months

Thinly traded micro cap Nymox Pharmaceutical Corp. (NYMX +8.3%) perks up on almost double normal volume, albeit on turnover of only 264K shares, on the heels of its announcement that its lead fexapotide program in benign prostatic hyperplasia (enlarged prostate) is on track despite COVID-19 disruptions.

It expects to file marketing applications in late Q3/early Q4.

Fexapotide triflutate (NX-1207) is a pro-apoptotic (promotes cell death) protein administered directly into the prostate via a transrectal injection that does not require anesthesia or sedation.

https://seekingalpha.com/news/3584613-nymoxplus-8-on-track-to-file-fexapotide-applications-in-four-months